Subjective and physiological effects, and expired carbon monoxide concentrations in frequent and occasional cannabis smokers following smoked, vaporized, and oral cannabis administration

Drug and Alcohol Dependence

Volumn 175, Issue , 2017, Pages 67-76

  Newmeyer, Matthew N ^a,b   Swortwood, Madeleine J ^a,c   Abulseoud, Osama A ^a   Huestis, Marilyn A ^a,d  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c SAM HOUSTON STATE UNIVERSITY   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Cannabis; Carbon monoxide; Edibles; Heart rate; Subjective effects

Indexed keywords

CANNABIS; CARBON MONOXIDE; TETRAHYDROCANNABINOL;

ADULT; AGGRESSION; ANGER; ANXIETY; ARTICLE; BREATHING RATE; CANNABIS SMOKING; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DYSPNEA; FEMALE; HEART RATE; HUMAN; HUNGER; IRRITABILITY; MALE; RESTLESSNESS; SEDATION; SMOKE; STUDY DESIGN; SYSTOLIC BLOOD PRESSURE; VAPORIZATION; ADOLESCENT; BREATH ANALYSIS; COMPARATIVE STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; DRUG TOLERANCE; MENTAL FUNCTION; METABOLISM; MIDDLE AGED; NEBULIZER; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; BREATH TESTS; CARBON MONOXIDE; DOUBLE-BLIND METHOD; DRUG TOLERANCE; FEMALE; HEART RATE; HUMANS; MALE; MARIJUANA SMOKING; MENTAL PROCESSES; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; YOUNG ADULT;

EID: 85017266926     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2017.02.003     Document Type: Article

References (34)

1. Abrams, D.I., Vizoso, H.P., Shade, S.B., Jay, C., Kelly, M.E., Benowitz, N.L., Vaporization as a smokeless cannabis delivery system: a pilot study. Clin. Pharmacol. Ther. 82 (2007), 572–578, 10.1038/sj.clpt.6100200.
2. Auwärter, V., Wohlfarth, A., Traber, J., Thieme, D., Weinmann, W., Hair analysis for Δ9-tetrahydrocannabinolic acid A—new insights into the mechanism of drug incorporation of cannabinoids into hair. Forensic Sci. Int. 196 (2010), 10–13, 10.1016/j.forsciint.2009.12.023.
3. Barnett, G., Chiang, C.W.N., Perez-Reyes, M., Ownes, S.M., Kinetic study of smoking marijuana. J. Pharmacokinet. Biopharm. 10 (1982), 495–506, 10.1007/BF01059033.
4. 9-THC and smoked marijuana in humans. Psychopharmacology (Berl.) 107 (1992), 255–262, 10.1007/BF02245145.
5. Chiang, C.W.N., Barnett, G., Marijuana effect and delta-9-tetrahydrocannabinol plasma level. Clin. Pharmacol. Ther. 36 (1984), 234–238, 10.1038/clpt.1984.168.
6. Cocchetto, D.M., Owens, S.M., Perez-Reyes, M., Di Guiseppi, S., Miller, L.L., Relationship between plasma delta-9-tetrahydrocannabinol concentration and pharmacologic effects in man. Psychopharmacology (Berl.) 75 (1981), 158–164, 10.1007/BF00432179.
7. Cone, E.J., Huestis, M.A., Relating blood concentrations of tetrahydrocannabinol and metabolites to pharmacologic effects and time of marijuana usage. Ther. Drug Monit. 15 (1993), 527–532.
8. Cone, E.J., Johnson, R.E., Paul, B.D., Mell, L.D., Mitchell, J., Marijuana-laced brownies: behavioral effects, physiologic effects, and urinalysis in humans following ingestion. J. Anal. Toxicol. 12 (1988), 169–175, 10.1093/jat/12.4.169.
9. Desrosiers, N.A., Himes, S.K., Scheidweiler, K.B., Concheiro-Guisan, M., Gorelick, D.A., Huestis, M.A., Phase I and II cannabinoid disposition in blood and plasma of occasional and frequent smokers following controlled smoked cannabis. Clin. Chem. 60 (2014), 631–643, 10.1373/clinchem.2013.216507.
10. Desrosiers, N.A., Ramaekers, J.G., Chauchard, E., Gorelick, D.A., Huestis, M.A., Smoked cannabis’ psychomotor and neurocognitive effects in occasional and frequent smokers. J. Anal. Toxicol. 39 (2015), 251–261, 10.1093/jat/bkv012.
11. 9-THC in cannabis products. Forensic Sci. Int. 149 (2005), 3–10, 10.1016/j.forsciint.2004.05.015.
12. Frederiksen, L.W., Martin, J.E., Carbon monoxide and smoking behavior. Addict. Behav. 4 (1979), 21–30, 10.1016/0306-4603(79)90017-0.
13. Gorelick, D.A., Goodwin, R.S., Schwilke, E., Schwope, D.M., Darwin, W.D., Kelly, D.L., McMahon, R.P., Liu, F., Ortemann-Renon, C., Bonnet, D., Huestis, M.A., Tolerance to effects of high-dose oral Δ9-tetrahydrocannabinol and plasma cannabinoid concentrations in male daily cannabis smokers. J. Anal. Toxicol. 37 (2013), 11–16, 10.1093/jat/bks081.
14. 9-tetrahydrocannabinol in humans. Psychopharmacology (Berl.) 164 (2002), 407–415, 10.1007/s00213-002-1231-y.
15. Hartman, R.L., Brown, T.L., Milavetz, G., Spurgin, A., Gorelick, D.A., Gaffney, G., Huestis, M.A., Controlled vaporized cannabis, with and without alcohol: subjective effects and oral fluid-blood cannabinoid relationships. Drug Test Anal. 8 (2016), 690–701, 10.1002/dta.1839.
16. ®) for the pulmonary administration of tetrahydrocannabinol. J. Pharm. Sci. 95 (2006), 1308–1317, 10.1002/jps.20574.
17. 9-tetrahydrocannabinol. Pharmacology 11 (1974), 3–11, 10.1159/000136462.
18. Institute of Medicine, Marijuana and Medicine: Assessing the Science Base. 1999, National Academy Press, Washington, DC.
19. Jones, R.T., Benowitz, N., Bachman, J., Clinical studies of cannabis tolerance and dependence. Ann. N. Y. Acad. Sci. 282 (1976), 221–239, 10.1111/j.1749-6632.1976.tb49901.x.
20. Jung, J., Kempf, J., Mahler, H., Weinmann, W., Detection of Δ9-tetrahydrocannabinolic acid A in human urine and blood serum by LC–MS/MS. J. Mass Spectrom. 42 (2007), 354–360, 10.1002/jms.1167.
21. 9-tetrahydrocannabinol. J. Clin. Invest. 52 (1973), 2411–2417, 10.1172/JCI107431.
22. Moore, C., Rana, S., Coulter, C., Simultaneous identification of 2-carboxy-tetrahydrocannabinol, tetrahydrocannabinol, cannabinol and cannabidiol in oral fluid. J. Chromatogr. B 852 (2007), 459–464, 10.1016/j.jchromb.2007.02.016.
23. Moosmann, B., Roth, N., Auwärter, V., Hair analysis for THCA-A, THC and CBN after passive in vivo exposure to marijuana smoke. Drug Test. Anal. 6 (2014), 119–125, 10.1002/dta.1474.
24. Newmeyer, M.N., Swortwood, M.J., Barnes, A.J., Abulseoud, O.A., Scheidweiler, K.B., Huestis, M.A., Free and glucuronide cannabinoids’ pharmacokinetics after controlled smoked, vaporized and oral cannabis administration in frequent and occasional cannabis users: identification of recent cannabis intake. Clin. Chem. 62 (2016), 1579–1592, 10.1373/clinchem.2016.263475.
25. Ohlsson, A., Lindgren, J.E., Wahlen, A., Agurell, S., Hollister, L.E., Gillespie, H.K., Plasma delta-9-tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin. Pharmacol. Ther. 28 (1980), 409–416, 10.1038/clpt.1980.181.
26. Raikos, N., Schmid, H., Nussbaumer, S., Ambach, L., Lanz, S., Längin, A., König, S., Roth, N., Auwärter, V., Weinmann, W., Determination of Δ9-tetrahydrocannabinolic acid A (Δ9-THCA-A) in whole blood and plasma by LC–MS/MS and application in authentic samples from drivers suspected of driving under the influence of cannabis. Forensic Sci. Int. 243 (2014), 130–136, 10.1016/j.forsciint.2014.07.026.
27. Schauer, G.L., King, B.A., Bunnell, R.E., Promoff, G., McAfee, T.A., Toking, vaping, and eating for health or fun: marijuana use patterns in adults, U.S., 2014. Am. J. Prev. Med. 50 (2016), 1–8, 10.1016/j.amepre.2015.05.027.
28. Schwope, D.M., Karschner, E.L., Gorelick, D.A., Huestis, M.A., Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration. Clin. Chem. 57 (2011), 1406–1414, 10.1373/clinchem.2011.171777.
29. 9-tetrahydrocannabinol concentrations in heavy, chronic cannabis smokers following acute smoked cannabis. J. Anal. Toxicol. 36 (2012), 405–412, 10.1093/jat/bks044.
30. Swortwood, M.J., Newmeyer, M.N., Abulseoud, O.A., Scheidweiler, K.B., Huestis, M.A., Cannabinoid disposition in oral fluid after controlled smoked, vaporized, and oral cannabis administration. Drug Test. Anal., 2016, 10.1002/dta.2092.
31. Vandrey, R., Raber, J.C., Raber, M.E., Douglass, B., Miller, C., Bonn-Miller, M.O., Cannabinoid dose and label accuracy in edible medical cannabis products. JAMA 313 (2015), 2491–2493, 10.1001/jama.2015.6613.
32. 9-tetrahydrocannabinol and marijuana in humans. Psychopharmacology (Berl.) 161 (2002), 331–339, 10.1007/s00213-002-1033-2.
33. Wu, T.C., Tashkin, D., Djahed, B., Rose, J., Pulmonary hazards of smoking marijuana as compared with tobacco. N. Engl. J. Med. 318 (1988), 347–351, 10.1056/NEJM198802113180603.
34. Zuurman, L., Roy, C., Schoemaker, R., Hazekamp, A., den Hartigh, J., Bender, J., Verpoorte, R., Pinquier, J., Cohen, A., van Gerven, J., Effect of intrapulmonary tetrahydrocannabinol administration in humans. J. Psychopharm. 22 (2008), 707–716, 10.1177/0269881108089581.